Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm, Inc. to Report Pharmacokinetic Data From Intranasal Human Abuse Liability Study on Second Quarter Conference Call

GlobeNewswire August 13, 2015

KemPharm, Inc. to Report Q2 2015 Results

GlobeNewswire August 6, 2015

KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference

GlobeNewswire August 4, 2015

KemPharm, Inc. to Present at Canaccord Genuity 35th Annual Growth Conference

GlobeNewswire August 4, 2015

KemPharm, Inc. Announces Changes to Senior Leadership to Target Strategic Opportunities

GlobeNewswire June 25, 2015

KemPharm, Inc. Reports Positive Data From Oral Human Abuse Liability Clinical Trial of KP201/APAP

GlobeNewswire June 11, 2015

KemPharm, Inc. Reports Q1 2015 Results

GlobeNewswire May 27, 2015

KemPharm Completes Pre-NDA Meeting With FDA for KP201/APAP

GlobeNewswire May 21, 2015

KemPharm's KP201/APAP Featured at the 2015 Abuse Deterrent Formulations Summit

GlobeNewswire May 19, 2015

KemPharm, Inc. to Report Q1 2015 Results

GlobeNewswire May 18, 2015

KemPharm Announces Pricing of Initial Public Offering

GlobeNewswire April 15, 2015